Adagene Inc(NASDAQ:ADAG) 
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. Its products include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase Ib clinical trials for the ...
Website: http://www.adagene.com
Founded: 2011
CEO: Peter Luo
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 1.64
H 1.64
L 1.54
C 1.58
V 1,880
10EMA 1.58
20EMA 1.58
60EMA 1.58
120EMA 1.58
250EMA 1.58